Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a note issued to investors on Friday, Benzinga reports. They currently have a $11.00 price target on the stock.

Several other analysts have also recently weighed in on VOR. JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Friday, March 22nd. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research note on Thursday, March 21st. HC Wainwright reiterated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Thursday, March 21st. Finally, Stifel Nicolaus decreased their price target on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $13.50.

Vor Biopharma Stock Performance

NYSE VOR traded down $0.11 during trading hours on Friday, hitting $1.70. 133,477 shares of the company traded hands, compared to its average volume of 287,512. Vor Biopharma has a twelve month low of $1.62 and a twelve month high of $5.70. The stock has a market capitalization of $115.97 million, a price-to-earnings ratio of -0.97 and a beta of -0.23. The business’s 50-day moving average is $1.96 and its 200-day moving average is $2.07.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. Analysts predict that Vor Biopharma will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Vor Biopharma

An institutional investor recently raised its position in Vor Biopharma stock. Exchange Traded Concepts LLC increased its position in shares of Vor Biopharma Inc. (NYSE:VOR) by 34.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 60,170 shares of the company’s stock after acquiring an additional 15,258 shares during the period. Exchange Traded Concepts LLC owned about 0.09% of Vor Biopharma worth $135,000 at the end of the most recent reporting period. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.